Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunocore Holdings plc IMCR

Healthcare Biotechnology
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and... see more

Recent & Breaking News (NDAQ:IMCR)

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 19 hours ago

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 4 days ago

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

GlobeNewswire 8 days ago

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

GlobeNewswire December 23, 2024

Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

GlobeNewswire December 17, 2024

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

GlobeNewswire December 11, 2024

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

GlobeNewswire December 3, 2024

Immunocore to present at upcoming investor conferences

GlobeNewswire November 8, 2024

Immunocore reports third quarter financial results and provides a business update

GlobeNewswire November 6, 2024

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

GlobeNewswire September 14, 2024

Immunocore to present at the 2024 Cantor Global Healthcare Conference

GlobeNewswire September 12, 2024

Immunocore announces transition of Chief Financial Officer

GlobeNewswire August 29, 2024

Immunocore reports second quarter financial results and provides a business update

GlobeNewswire August 8, 2024

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

GlobeNewswire August 1, 2024

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

GlobeNewswire June 18, 2024

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

GlobeNewswire June 1, 2024

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

GlobeNewswire May 31, 2024

Immunocore to present at the Jefferies Global Healthcare Conference

GlobeNewswire May 30, 2024

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

GlobeNewswire May 29, 2024

Immunocore reports first quarter financial results and provides a business update

GlobeNewswire May 8, 2024